Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1189050 | 0.84 | ALDH1A1 (0.52) | MEN1KMT2ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL3665666 | 0.84 | ALOX15 (0.43) | — | |
| SCHEMBL2059424 | 0.82 | ALOX15 (0.43) | ALDH1A1CYP1A2HPGD | |
| SCHEMBL2059299 | 0.82 | ALOX15 (0.43) | ALDH1A1CYP1A2HPGD | |
| SCHEMBL1187666 | 0.82 | ALOX15 (0.43) | ALDH1A1CYP1A2HPGDPOLBMAPK1 | |
| SCHEMBL1187895 | 0.82 | ALOX15 (0.43) | ALDH1A1CYP1A2HPGD | |
| SCHEMBL1188579 | 0.80 | ALOX15 (0.44) | ALDH1A1POLBTSHR | |
| SCHEMBL1188341 | 0.80 | ALOX15 (0.44) | ALDH1A1POLBTSHR | |
| SCHEMBL22630563 | 0.79 | ALOX15 (0.43) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL1187917 | 0.79 | ALOX15 (0.43) | ALDH1A1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179542-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2021-06-17 | — | — | US | claimed |
| US-20190270699-A1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2019-09-05 | — | — | US | claimed |
| US-9546132-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | claimed |
| US-20160075638-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2016-03-17 | — | — | US | claimed |
| EP-2220030-B1 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | EDISON PHARMACEUTICALS INC (US) | 2016-01-13 | — | — | EP | claimed |
| US-9169196-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | EDISON PHARMACEUTICALS, INC. (US) | 2015-10-27 | — | — | US | claimed |
| US-20130289034-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2013-10-31 | — | — | US | claimed |
| EP-2220030-A2 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | Edison Pharmaceuticals, Inc. (US) | 2010-08-25 | — | — | EP | claimed |
| WO-2009061744-A2 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | claimed |
| US-20090118257-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2009-05-07 | — | — | US | claimed |
| EP-3733642-B1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS INC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11840497-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | PTC THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20210322337-A1 | TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS | PTC THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210179542-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2021-06-17 | — | — | US | disclosed |
| US-10968166-B2 | 4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | PTC THERAPEUTICS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| EP-2220030-A2 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | Edison Pharmaceuticals, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2010045220-A1 | TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS | EDISON PHARMACEUTICALS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009111543-A2 | TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS | EDISON PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009061744-A2 | 4- (P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | EDISON PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118257-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | PTC THERAPEUTICS, INC. | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270699-A1 | 4-(P-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | FASN 318/4885BLM 3971/4885MEN1 3606/4885 |
| US-20130289034-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | FASN 331/4885BLM 3944/4885MEN1 3518/4885 |
| US-20160075638-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | FASN 331/4885BLM 3944/4885MEN1 3518/4885 |
| US-11840497-B2 | 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | FH, NLN, ACAA2 | FASN 331/4885BLM 3944/4885MEN1 3518/4885 |
| US-20210179542-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | FASN 331/4885BLM 3944/4885MEN1 3518/4885 |
| US-20090118257-A1 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES | FH, NLN, ACAA2 | FASN 331/4885BLM 3944/4885MEN1 3518/4885 |
| US-20210322337-A1 | TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS | GPX4, TXN2, TXNRD1 | FASN 2656/4885BLM 2840/4885MEN1 3277/4885 |
| US-10968166-B2 | 4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases | FH, NLN, ACAA2 | FASN 318/4885BLM 3971/4885MEN1 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.